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The cocrystal structure of the heterodimer GPCR extracellular domain complex of the CGRP receptor (CLR
and RAMP1) has been determined in an apo form and with two different antagonists olcegepant and telca-
gepant (ter Haar et al., 2010).A key challenge in the G protein-coupled
receptor (GPCR) area of pharmacological
research concerns the secretin or class-BFigure 1. Phylogenetic Tree of Class-B GPCRs Highlighting
Known Structures for Several of the ECDs
The X-ray and NMR structures of class-B GPCR ECD alone or bound to its
cognatepeptide-ligandareshownnext to the receptoron thephylogenentic
tree. The ECDs are in green, and the peptide ligands are in different colors.
The structures are the human glucose-dependent insulinotropic polypepe-
tide receptor (GIPR) bound to GIP (PDB: 2QKH), a subtype of human
pituitary adenylate cyclase-activating polypeptide receptor (PACAPR)
bound to PACAP (PDB: 2JOD), human glucagon-like peptide-1 receptor
(GLP1R) bound to exendin-4 (competitive antagonist) (PDB: 3C5T),
GLP1R bound to GLP1 (PDB: 3IOL), human parathyroid hormone receptor
1 (PTHR1) (PDB: 3L2J), PTHR1 bound to PTH (PDB: 3C4M), PTHR1 bound
to PTH-related peptide (PDB: 3H3G), and murine type-2b corticotrophin-
releasing factor receptor (CRFR2) bound to astressin (competitive antago-
nist) (PDB: 2JND), human type-1 CRF receptor (CRFR1) (PDB: 3EHS),
CRFR1 bound to CRF (PDB: 3EHT and 3EHU), and vasoactive intestinal
peptide receptor 2 (VIPR2) (PDB: 2X57). GLR,SCTR, andGHRHRrepresent
the glucagon, secretin, and growth-hormone releasing hormone receptors.
Variable pharmacology of the calcitonin (CTR) and calcitonin receptor-like
receptors (CLR) results from interactions with RAMP proteins. In this repre-
sentation, CTR represents the heterodimers of CTR and RAMPs, while
CGRPR represent the CLR/RAMP1 complex, highlighting the new struc-
tures determined by ter Haar et al. (2010) in this issue of Structure.family of receptors. The class-B
GPCR family is comprised of
15 members, each of which is
defined by their relatively large
and unique 100-160 residue
N-terminal extracellular or ecto-
domain (ECD) that contains
threeconserveddisulfidebonds
and the canonical seven trans-
membrane helix (7TM) motif
(Hoare, 2005). These GPCRs
utilize their ECD to recognize
polypeptide hormones of about
30–40 amino acids, which in-
clude parathyroid hormone
(PTH), glucagon-like peptide
(GLP), calcitonin (CT), and the
calcitonin gene-related peptide
(CGRP). Several of these recep-
tors form heterodimers with
receptor activity-modifying pro-
teins (RAMPs) as they fulfill their
role in signaling pathways (Con-
ner et al., 2004). Analogs of the
native peptide hormones have
been developed as peptide an-
tagonists for therapeutic uses,
but these analogs typically
havepoorpharmacological pro-
perties for clinical application.
Thus, nonpeptide agonists or
antagonists have been in the
focus of drug development
efforts for many of the class-B
GPCRs.
For many of these receptors,
the peptide-ligand specificity is
primarily associated with the
ECD, with secondary recogni-
tion and signaling through the
7TM domain. Several structures
of class-B ECDs bound to their
cognate peptide-ligands illus-trate thispoint clearly (Figure1) (for a review
of class-B ECD structures, see Parthier
et al. (2009)). The canonical class-B ECDStructure 18, September 8, 2010 ªhas two central antiparallel b sheets and
an N-terminal a helix interconnected by
several loops and stabilized by the three2010 Elseconserved disulfide bonds.
Based on these structures and
biochemical analyses, a ‘‘two
domain’’ model has emerged in
which the C-terminal portion of
the peptide-ligand is recognized
by theECD,while theN-terminal
portion of the peptide inter-
acts with the 7TM domain of
the receptor. From the ECD
peptide-ligand complex struc-
tures, it can be seen that the
C-terminalportionof thepeptide
is an a helix that interacts with
the two b sheets and loops of
the ECD by specific residues
between the peptide and ECD.
For the two class-B GPCRs,
the CT (CTR) and CT receptor-
like (CLR) receptors, ligand
specificity is defined by the
heterodimerization of the ECD
withoneof threeRAMPproteins
(for a review of RAMPs and
class-B GPCRs, see Sexton
et al. (2006) and Walker et al.
(2010)). CTR interacts with
RAMP1,2, and3,with eachhet-
erodimer generating a different
phenotype responding to the
amylin peptide. Heterodimers
of the CLR with RAMP1, 2,
and 3 display different affinities
for the CGRP and adrenome-
dullin (AM) peptides (Hay et al.,
2004). The CLR/RAMP1 com-
plex has higher affinity for
CGRP, whereas the CLR/
RAMP2complex is selective for
AM. The CLR/RAMP3 complex
has mixed specificities and
can be activated by CGRP and
AM. The level of CGRPvier Ltd All rights reserved 1067
Figure 2. Physiological Function of CLR/RAMP1 Heterodimer
Receptor and the Role of Two Nonpeptide Antagonists
CGRP level is elevated in the brain during migraine attacks, triggering the
throbbing and pulsating pain through the CLR/RAMP1 receptor complex.
CLR is a class-B GPCR (purple) that dimerizes with RAMP1 (orange). Recog-
nition of CGRP (green spheres) is determined by the heterodimer of the
extracellular domains (ECD) of CLR and RAMP1. Two selective nonpeptide
antagonists, olcegepant (BIBN4096BS) and telcagepant (MK0974) (depicted
as blue spheres), compete for the binding of CGRP to the CLR/RAMP1
receptor complex and are effective in treating migraines in clinical trials. The
structures determined by ter Haar et al. (2010) show the interactions of the
ECDs of CLR and RAMP1, and the bindingmechanisms of the two antagonists
to the ECD complex. Modified from Williams et al. (2009).
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Previewsincreases during migraines
(Figure 2); thus, the two
nonpeptideantagonists, olce-
gepant (BIBN4096BS) and
telcagepant (MK0974), have
been developed against the
CLR/RAMP1 complex as
therapeutic agents (Figure 2).
Both antagonists compete
with the binding of CGRP
to the heterodimer and are
efficacious in treating acute
migraine in clinical trials.
However, critical details are
missing regarding the selec-
tivity and site of binding of
these nonpeptide antagonists
to the CLR/RAMP1 complex.
In the article by ter Haar
et al. (2010) in this issue of
Structure, researchers at Ver-
tex Pharmaceuticals present
structural details of the
class-B GPCR (CLR) in
complex with RAMP1 (Fig-
ure 1). Overall, the ECD struc-
ture of CLR is similar to other
class-B ECD structures. The
RAMP1 ECD structure in the
complex is a 3-helix bundle
stabilized by the three disul-
fidebonds.Surprisingly, com-
parison of the structures of
the RAMP1 ECD homodimer
with the CLR/RAMP1 ECD
heterodimer shows no signifi-
cant conformational rear-
rangement of RAMP1 when
bound to CLR or vice versa.
Dimerization of the CLR andHoare,S.R. (20RAMP1 ECDs is formed by hydrophobic
and electrostatic interactions between
the N-terminal helix of CLR, and helix 2
and 3 of RAMP1.
The CLR/RAMP1 ECD heterodimer has
also been determined in complex with
olcegepant and telcagepant, detailing crit-
ical drug-receptor interactions. The struc-
tures show that Thr122 of CLR forms
hydrogen bonds with both antagonists. In
addition, Trp72 of CLR and Trp74 of
RAMP1 form the necessary hydrophobic
interaction with both antagonists, high-
lighting the importance of the heterodimer
for proper antagonist binding. The struc-
tures provide an explanation for the high1068 Structure 18, September 8, 2010 ª2010selectivity of olcegepant and telcagepant
to CLR/RAMP1 relative to CLR/RAMP2
and CLR/RAMP3. Trp74 of RAMP1 is
replaced with the nonconserved Glu in
RAMP2 and 3. Although telcagepant
(KD=1.9nM) isnot aspotent asolcegepant
(KD = 45 pM), the two structures illustrate
that telcagepant establishes more specific
contacts with CLR/RAMP1. The azabenzi-
midazolone group of telcagepant forms
an additional hydrogen bond with Thr122
of CLR, while the difluorophenyl group
increases the hydrophobic interaction
with CLR and RAMP1 by displacing a
bound water molecule that is observed in
the olcegepant structure.Elsevier Ltd All rights reservedWhile these structures do
not address the key mecha-
nistic hypothesis put forth in
the two-domain model (that
will have to wait for a full-
length receptor structure), the
work by ter Haar et al. (2010)
is exceptional and highlights
the mechanism of small mole-
cule antagonism and the chal-
lenges of antagonist design.
A number of new experiments
will follow based on these
exciting results and provides
a much needed advance in
the field of membrane protein
structural biology, and specif-
ically our improved under-
standing of GPCR structure
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